- Home
- ACCS vs GANX Comparison
ACCS vs GANX Comparison
Compare ACCS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- GANX
- Stock Information
- Founded
- ACCS 1988
- GANX 2017
- Country
- ACCS United States
- GANX United States
- Employees
- ACCS N/A
- GANX N/A
- Industry
- ACCS Publishing
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- ACCS Consumer Discretionary
- GANX Health Care
- Exchange
- ACCS Nasdaq
- GANX Nasdaq
- Market Cap
- ACCS 44.2M
- GANX 51.8M
- IPO Year
- ACCS N/A
- GANX 2021
- Fundamental
- Price
- ACCS $12.20
- GANX $1.44
- Analyst Decision
- ACCS Strong Buy
- GANX Strong Buy
- Analyst Count
- ACCS 1
- GANX 5
- Target Price
- ACCS $15.00
- GANX $8.20
- AVG Volume (30 Days)
- ACCS 14.6K
- GANX 276.2K
- Earning Date
- ACCS 08-11-2025
- GANX 08-11-2025
- Dividend Yield
- ACCS N/A
- GANX N/A
- EPS Growth
- ACCS N/A
- GANX N/A
- EPS
- ACCS N/A
- GANX N/A
- Revenue
- ACCS $22,961,000.00
- GANX N/A
- Revenue This Year
- ACCS $3.05
- GANX N/A
- Revenue Next Year
- ACCS $15.47
- GANX N/A
- P/E Ratio
- ACCS N/A
- GANX N/A
- Revenue Growth
- ACCS 6.92
- GANX N/A
- 52 Week Low
- ACCS $7.79
- GANX $0.89
- 52 Week High
- ACCS $13.35
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- GANX 34.87
- Support Level
- ACCS N/A
- GANX $1.55
- Resistance Level
- ACCS N/A
- GANX $1.72
- Average True Range (ATR)
- ACCS 0.00
- GANX 0.12
- MACD
- ACCS 0.00
- GANX -0.02
- Stochastic Oscillator
- ACCS 0.00
- GANX 6.12
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.